Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma

Anil Potti, Nauman Moazzam, Eric Langness, Kaley Sholes, Ketki Tendulkar, Michael Koch, Steve Kargas

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: To determine the prevalence and evaluate the possible prognostic value of the molecular targets in malignant melanoma, we studied the overexpression of HER-2/neu, c-Kit, and vascular endothelial growth factor (VEGF) in this patient population. Materials and methods: Overexpression of HER-2/neu, c-Kit, and VEGF was evaluated using immunohistochemical assays in 202 archival tissue specimens. Results: Only two patients (0.9%) revealed HER-2/neu overexpression, whereas 46 (22.8%) revealed c-Kit and 42 (20.8%) specimens showed VEGF overexpression. Multivariate analysis performed did not show a significant difference in survival between c-Kit-positive and c-Kit-negative groups (P = 0.36) and VEGF-positive and VEGF-negative groups (P = 0.25). Interestingly, c-Kit was more likely to be overexpressed in the superficial spreading type and VEGF was overexpressed preferentially in the amelanotic melanoma type. Conclusions: HER-2/neu has no role in melanogenesis. Both c-Kit (expressed in superficial spreading disease) and VEGF (expressed in amelanotic melanoma) may have significant therapeutic implications as molecular targets, which warrants further investigation.

Original languageEnglish (US)
Pages (from-to)80-86
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume130
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Vascular Endothelial Growth Factor A
Melanoma
Amelanotic Melanoma
Multivariate Analysis
Survival
Population

Keywords

  • HER-2/neu
  • Immunohistochemical
  • Melanoma
  • VEGF
  • c-kit

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. / Potti, Anil; Moazzam, Nauman; Langness, Eric; Sholes, Kaley; Tendulkar, Ketki; Koch, Michael; Kargas, Steve.

In: Journal of Cancer Research and Clinical Oncology, Vol. 130, No. 2, 01.02.2004, p. 80-86.

Research output: Contribution to journalArticle

@article{5a3b9660ae96431c878f6d7f7f214017,
title = "Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma",
abstract = "Purpose: To determine the prevalence and evaluate the possible prognostic value of the molecular targets in malignant melanoma, we studied the overexpression of HER-2/neu, c-Kit, and vascular endothelial growth factor (VEGF) in this patient population. Materials and methods: Overexpression of HER-2/neu, c-Kit, and VEGF was evaluated using immunohistochemical assays in 202 archival tissue specimens. Results: Only two patients (0.9{\%}) revealed HER-2/neu overexpression, whereas 46 (22.8{\%}) revealed c-Kit and 42 (20.8{\%}) specimens showed VEGF overexpression. Multivariate analysis performed did not show a significant difference in survival between c-Kit-positive and c-Kit-negative groups (P = 0.36) and VEGF-positive and VEGF-negative groups (P = 0.25). Interestingly, c-Kit was more likely to be overexpressed in the superficial spreading type and VEGF was overexpressed preferentially in the amelanotic melanoma type. Conclusions: HER-2/neu has no role in melanogenesis. Both c-Kit (expressed in superficial spreading disease) and VEGF (expressed in amelanotic melanoma) may have significant therapeutic implications as molecular targets, which warrants further investigation.",
keywords = "HER-2/neu, Immunohistochemical, Melanoma, VEGF, c-kit",
author = "Anil Potti and Nauman Moazzam and Eric Langness and Kaley Sholes and Ketki Tendulkar and Michael Koch and Steve Kargas",
year = "2004",
month = "2",
day = "1",
doi = "10.1007/s00432-003-0509-8",
language = "English (US)",
volume = "130",
pages = "80--86",
journal = "Zeitschrift fur Krebsforschung und Klinische Onkologie",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma

AU - Potti, Anil

AU - Moazzam, Nauman

AU - Langness, Eric

AU - Sholes, Kaley

AU - Tendulkar, Ketki

AU - Koch, Michael

AU - Kargas, Steve

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Purpose: To determine the prevalence and evaluate the possible prognostic value of the molecular targets in malignant melanoma, we studied the overexpression of HER-2/neu, c-Kit, and vascular endothelial growth factor (VEGF) in this patient population. Materials and methods: Overexpression of HER-2/neu, c-Kit, and VEGF was evaluated using immunohistochemical assays in 202 archival tissue specimens. Results: Only two patients (0.9%) revealed HER-2/neu overexpression, whereas 46 (22.8%) revealed c-Kit and 42 (20.8%) specimens showed VEGF overexpression. Multivariate analysis performed did not show a significant difference in survival between c-Kit-positive and c-Kit-negative groups (P = 0.36) and VEGF-positive and VEGF-negative groups (P = 0.25). Interestingly, c-Kit was more likely to be overexpressed in the superficial spreading type and VEGF was overexpressed preferentially in the amelanotic melanoma type. Conclusions: HER-2/neu has no role in melanogenesis. Both c-Kit (expressed in superficial spreading disease) and VEGF (expressed in amelanotic melanoma) may have significant therapeutic implications as molecular targets, which warrants further investigation.

AB - Purpose: To determine the prevalence and evaluate the possible prognostic value of the molecular targets in malignant melanoma, we studied the overexpression of HER-2/neu, c-Kit, and vascular endothelial growth factor (VEGF) in this patient population. Materials and methods: Overexpression of HER-2/neu, c-Kit, and VEGF was evaluated using immunohistochemical assays in 202 archival tissue specimens. Results: Only two patients (0.9%) revealed HER-2/neu overexpression, whereas 46 (22.8%) revealed c-Kit and 42 (20.8%) specimens showed VEGF overexpression. Multivariate analysis performed did not show a significant difference in survival between c-Kit-positive and c-Kit-negative groups (P = 0.36) and VEGF-positive and VEGF-negative groups (P = 0.25). Interestingly, c-Kit was more likely to be overexpressed in the superficial spreading type and VEGF was overexpressed preferentially in the amelanotic melanoma type. Conclusions: HER-2/neu has no role in melanogenesis. Both c-Kit (expressed in superficial spreading disease) and VEGF (expressed in amelanotic melanoma) may have significant therapeutic implications as molecular targets, which warrants further investigation.

KW - HER-2/neu

KW - Immunohistochemical

KW - Melanoma

KW - VEGF

KW - c-kit

UR - http://www.scopus.com/inward/record.url?scp=1542343818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542343818&partnerID=8YFLogxK

U2 - 10.1007/s00432-003-0509-8

DO - 10.1007/s00432-003-0509-8

M3 - Article

C2 - 14634801

AN - SCOPUS:1542343818

VL - 130

SP - 80

EP - 86

JO - Zeitschrift fur Krebsforschung und Klinische Onkologie

JF - Zeitschrift fur Krebsforschung und Klinische Onkologie

SN - 0171-5216

IS - 2

ER -